MA24

Canadian Cancer Trials Group - Tumour Bank
Logged in as: Public
Location: Home - Disease Sites - - MA24

MA24 Details
Status: Closed
Activation Date: 2002FEB07
Closing Date: 2004APR05
Phase: III

Description: A Randomized Three-Arm Multi-Centre Comparison of 1 Year and 2 Years of Herceptin versus no Herceptin in Women With HER2-positive Primary Breast Cancer Who Have Completed Adjuvant Chemotherapy

Eligibility: Women with primary breast cancer that over-expresses HER2 (determined by IHC 3+ or FISH positive) who have completed (neo-) adjuvant systemic chemotherapy and radiotherapy, if applicable.

Objective: To compare disease-free survival (DFS) in patients with HER2 overexpressing breast cancer who have been randomized to Herceptin? for one year versus no Herceptin?. To compare DFS in patients with HER2 overexpressing breast cancer who have been randomized to Herceptin? for two years versus no Herceptin?.

Participation: Open to member centres

Primary Publication Show

Other Publications Show

Year: 2005
Title: First results of the HERA trial
Authors: Piccart-Gebhart MJ;
Reference: 2005 May 16; ( )
Link:

Year: 2005
Title: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
Authors: Piccart-Gebhart MJ;Procter M;Leyland-Jones B;Goldhirsch A;Untch M;Smith I;Gianni L;Baselga J;Bell R;Jackisch C;Cameron D;Dowsett M;Barrios CH;Steger G;Huang C;Andersson M;Inbar M;Lichinitser M;Lang I;Nitz U;Iwata H;Thomssen C;Lohrisch C;Suter TM;Ruschoff J;Sut? T;Greatorex V;Ward C;Straehle C;McFadden E;Dolci S;Gelber RD;for the Herceptin Adjuvant (HERA) Trial Study Team;
Reference: New England Journal of Medicine 2005 Oct 20; 353 (16)
Link:

Year: 2007
Title: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Authors: Smith I;Procter M;Gelber RD;Guillaume S;Feyereislova A;Dowsett M;Goldhirsch A;Untch M;Mariani G;Baselga J;Kaufmann M;Cameron D;Bell R;Bergh J;Coleman R;Wardley A;Harbeck N;Lopez RI;Mallmann P;Gelmon K;Wilcken N;Wist E;Rovira PS;Piccart-Gebhart MJ;for the HERA study team;
Reference: Lancet 2007 Jan 6 ; 369 (9555)
Link:

Year: 2009
Title: Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA trial
Authors: Dowsett M;Procter M;McCaskill-Stevens W;de Azambuja E;Dafni U;Rueschoff J;Jordan B;Dolci S;Abramovitz M;Stoss O;Viale G;Gelber RD;Piccart-Gebhart M;Leyland-Jones B;
Reference: Journal of Clinical Oncology 2009 Jun 20; 27 (18)
Link: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2701645/?report=abstract

Year: 2012
Title: HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up
Authors: Goldhirsch A;Piccart-Gebhart MJ;Procter M;de Azambuja E;Weber HA;Untch M;Smith I;Gianni L;Jackisch C;Cameron D;Bell R;Dowsett M;Gelber RD;Leyland-Jones B;Baselga J;
Reference: Cancer Research 2012 Dec 15; 72 (24 Suppl 3, abstr S5-2)
Link: http://cancerres.aacrjournals.org/cgi/content/short/72/24_MeetingAbstracts/S5-2?rss=1

Inventory
Hide Tissue Samples

Disease Site	Trial Code	Patients Accrued	Patients - Blocks	Patients - Slides	Patients - Blocks and/or Slides
BREAST	MA24	160	6	0	6

Hide TMA Samples

(Core size is 0.6 mm)

Disease Site	Trial Code	Patients Accrued	TMA Blocks	Patients on TMA Blocks
BREAST	MA24	160	0	0

Hide Fluid Samples

Disease Site	Trial Code	Patients Accrued	Patients - Whole Blood	Patients - Cellular Component of Blood	Patients - DNA extracted from Blood	Patients - RNA extracted from Blood	Patients - Plasma	Patients - Serum	Patients - Urine	Patients - Buccal
BREAST	MA24	160	0	0	0	0	0	0	0	0